REGN Maintained by TD Cowen -- Price Target Raised to $980

gurufocus.com · 2026-10-21

Regeneron Pharmaceuticals: Analyst Rating Update and Valuation Insights On October 24, 2023, Regeneron Pharmaceuticals (REGN) received a new price target of

TickrTrends take: TD Cowen's decision to raise REGN's price target to $980 while maintaining its rating suggests the analyst sees limited upside from current levels, which aligns with TickrTrends' assessment that the stock is fairly valued. For investors focused on valuation metrics, this maintenance rating indicates that while the company's fundamentals may have improved enough to warrant a higher target price, the stock's current trading price already reflects reasonable expectations for the Healthcare sector company. The gap between the raised target and current market pricing would be the key metric to monitor for whether REGN remains fairly valued or becomes attractive based on fundamental developments.

Read the full story at gurufocus.com →